INTRODUCTION
Anaemia is the most common haematological complication associated with HIV, with rates increasing with disease progression. 1 Anaemia is independently associated with decreased quality of life, accelerated disease progression, and increases mortality in HIV-infected individuals. 2, 3 Survival time in HIV-infected individuals may be improved with recovery from anaemia. 1 By adversely affecting quality of life, anaemia may exacerbate poverty in communities with high HIV prevalence. 4 In developing countries such as India, where more than half of women in the general population are anaemic, 5 the interaction between HIV and anaemia may be even more detrimental. Estimates of the prevalence of anaemia among HIV-infected individuals in sub-Saharan Africa range from 70 -90%, 3,6 -8 as compared with 20 -60% reports from developed countries. 1, 9 Few studies have examined factors associated with anaemia in developing country settings. Risk factors for anaemia in developing countries may vary from those in developed countries due to endemic malnutrition, helminth infections, tuberculosis (TB), malaria and a different spectrum of opportunistic infections. Here we report the prevalence of, and factors associated with, anaemia among HIV-infected individuals at an HIV/AIDS tertiary care centre in South India.
METHODS
The YR Gaitonde Centre for AIDS Research and Education (YRG CARE) is an HIV tertiary care clinic in Chennai, India that has provided medical care to nearly 10,000 patients since 1994. Analysis was performed using the YRG CARE HIV Natural History Study Observational Database, which has been previously validated and approved by YRG CARE's independent institutional review board. 10 This database captures demographic and clinical details (including CD4 cell counts, haemoglobin values, opportunistic infections and HIV-related co-morbidities) from every patient visit. Patients greater than 18 years of age who visited between 1 January 1996 and 31 December 2006 were included. Only baseline haemoglobin values ordered at the time of a patient's initial enrollment for care were analysed.
Anaemia was classified by the following World Health Organization (WHO) criteria for both men and women: 'nonanaemic' (haemoglobin value !11 g/dL), grade one (9.5 -10.9 g/dL), grade two (8 -9.4 g/dL), grade three (6.5 -7.9 g/ dL) and grade four (,6.5 g/dL). For comparison with other studies, anaemia was also reclassified as haemoglobin values ,12 g/dL for women and ,13 g/dL for men as noted in the discussion. Body mass index (BMI) values, CD4 cell counts and HIV-associated co-morbidities recorded or diagnosed at the time of enrollment into care were included in the analysis. Statistical analyses were performed with SPSS (version 10.0.5; Chicago, IL, USA). Normal data were summarized using mean and standard deviation (SD) and non-normal data using median and interquartile range. Student's t-test was used to compare the mean haemoglobin values of the various CD4 cell count strata. Trends in anaemia grades among the different CD4 cell count strata were tested using x 2 for trend with Epi Info (version 3.3.2, CDC, Atlanta, GA, USA). Univariate and multivariate logistic regressions were performed to understand the associations between anaemia and the various demographic and clinical characteristics. Statistically significant variables (P , 0.05) were included in the multivariate model using the forward stepwise method, and the best reduced model was built based on a 2 log likelihood value.
RESULTS
In this analysis, 6996 patients who were over 18 years of age and had a haemoglobin value recorded at the time of enrollment into care were included, of whom 70% were men and 96% had acquired HIV through heterosexual transmission. Those without a haemoglobin value recorded at the time of enrollment into care, 2648 patients (27.5%), were excluded from all analyses. Male -female ratio, mean age and mean BMI between the included and excluded groups were similar. Specifically, patients included in the analysis had a 70% male predominance, a mean age of 33.6 years (SD 8.3) and a mean BMI of 20.1 (SD 2.8); this compares to a 63% male predominance, a mean age of 32.2 years (SD 8.0) and a mean BMI of 20.0 (SD 3.9) in the group excluded from the analysis.
The mean haemoglobin value for the entire cohort was 11.4 g/dL (SD 2.5). Using the WHO definition of anaemia, 41% of the cohort was anaemic, with 19% having grade one, 13% having grade two, 6% having grade three and 3% having grade four anaemia. Among the 4431 patients with CD4 cell count values available, the mean haemoglobin value declined from 12.6 g/dL at CD4 cell counts .500 cells/mL to 10.0 g/dL at CD4 cell counts ,100 cells/mL (P value for trend ,0.001, Figure 1 ). The percent of non-anaemic individuals decreased from 80% at CD4 cell counts .500 cells/mL to 36% at CD4 cell counts ,100 cells/mL (P , 0.001, Figure 1 ). There was a corresponding statistically significant increase in the percentage of patients with all grades of anaemia with declining CD4 cell count (Figure 1 ). Using the alternative definition of anaemia as any haemoglobin value ,12 g/dL for women and ,13 g/ dL for men, 69% of the entire cohort (72% of women and 67% of men) and 89% of patients with a CD4 cell count ,100 cell/mL were anaemic.
In the multivariate model, CD4 cell count ,100 cells/mL and underweight BMI were both associated with an approximately five times increased adjusted odds of anaemia (Table 1) . Female gender, extrapulmonary TB and pulmonary TB also had strong independent associations with anaemia. Age .31 years, oral and oesophageal candidiasis and generalized lymphadenopathy had milder independent associations with anaemia.
DISCUSSION
This study highlights the high prevalence of anaemia in HIV-infected individuals in south India, especially among immunosuppressed patients. Using a definition of anaemia as any haemoglobin value ,12 g/dL for women and ,13 g/dL for men, other developing country studies found a 70 -90% anaemia prevalence among HIV-infected individuals which is similar to the 69% found in our study. 3,6 -8 The 72% prevalence of anaemia among women in this study is significantly higher than the 50 -57% prevalence in large-scale surveys of women from the general population of the two south Indian states from which our clinic derives its patient population. 5 Most developing country studies have focused specifically on HIV-infected groups at higher risk for anaemia, such as pregnant or TB co-infected patients. Since this study has patients of both genders distributed across all CD4 cell count strata, it may more accurately reflect the prevalence of anaemia among HIV-infected individuals in India. In our study, the influence of HIV disease on anaemia starts well before patients are eligible for highly active antiretroviral therapy (HAART), with a significant increase in anaemia evident even at CD4 cell counts of 201 -350 cells/mL. Similar to prior findings, a low CD4 cell count has a strong independent association with anaemia even after controlling for opportunistic infections and malnutrition. 1, 11 This association may represent anaemia caused by the HIV virus itself, which may inhibit haematopoiesis directly through infection of progenitor cells or upregulation of cytokines. 8 Studies from developed countries suggest that HAART resolves anaemia in many patients, which is consistent with our finding that immunosuppression makes a strong independent contribution to anaemia. 9, 12 While a preliminary analysis from our clinic suggests a similar trend of anaemia resolution with HAART, 13 further prospective data are needed to answer this important question in developing countries.
The association of anaemia with low BMI is of specific relevance to India, where the rate of chronic malnutrition is among the highest in the world. 14 Interestingly, even individuals with a normal BMI had a two and a half times increased odds of anaemia as compared with those who were overweight. Low BMI is associated with many nutrient deficienciesincluding iron, folate and B 12 -that contribute directly to anaemia. The increased independent odds of anaemia with candida infection may also reflect micronutrient deficiency, since both oral and oesophageal infection decrease oral intake.
As TB is the second most common opportunistic infection in India (after oral candidiasis), 15 it may greatly exacerbate the burden of anaemia in this population. The aetiology of anaemia in TB is multifactorial, resulting from a combination of anaemia of chronic disease and deficiencies of nutrients such as iron, vitamin A and selenium. 6 The increased odds of anaemia in women most likely reflects the high rate of iron deficiency in Indian women due to menstrual blood loss, poor nutritional status and pregnancy. 5 Three of the strongest factors associated with anaemia -TB, immunosuppression and malnutrition -exacerbate each other in synergistic manner. The net result is a vicious cycle placing HIV-infected patients in TB-endemic countries at very high risk for developing anaemia. 6,7 Therefore, in addition to roll-out of HAART, nutritional support and aggressive TB control should be the cornerstones of anaemia management for HIV-infected individuals in India.
The main limitation of this analysis is its cross-sectional design, which precludes definite determination of the temporal relationships between anaemia and its associated factors. Also, our database does not capture laboratory findings (i.e. mean corpuscular volume, iron studies, etc.) that could clarify the frequency of anaemia due to particular nutrient deficiencies.
Finally, the high prevalence of anaemia in patients with CD4 cell counts ,200 cells/mL has implications for the choice of initial HAART regimen in developing countries. Since anaemia is an adverse effect of zidovudine (AZT), use of this drug is contraindicated in patients with pre-existing anaemia. 16, 17 Therefore, more than half of patients who meet criteria for HAART in this setting would not be eligible for initiation on a regimen that included AZT. This highlights the need for increased access to nucleoside reverse transcriptase inhibitors with different toxicity profiles, such as tenofovir and abacavir, in resource-limited settings.
